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Summary
Background Airway smooth muscle (ASM) hyperplasia and mast cell localization within the
ASM bundle are important features of asthma. The cause of this increased ASM mass is
uncertain and whether it is a consequence of ASM–mast cell interactions is unknown.
Objective We sought to investigate ASM proliferation and survival in asthma and the effects of
co-culture with mast cells.
Methods Primary ASM cultures were derived from 11 subjects with asthma and 12 non-
asthmatic controls. ASM cells were cultured for up to 10 days in the presence or absence of
serum either alone or in co-culture with the human mast cell line-1, unstimulated human lung
mast cells (HLMC) or IgE/anti-IgE-activated HLMC. Proliferation was assessed by cell counts,
CFSE assay and thymidine incorporation. Apoptosis and necrosis were analysed by Annexin
V/propidium iodide staining using ﬂow cytometry and by assessment of nuclear morphology
using immunoﬂuorescence. Mast cell activation was conﬁrmed by the measurement of
histamine release.
Results Using a number of techniques, we found that ASM proliferation and survival was not
signiﬁcantly different between cells derived from subjects with or without asthma. Co-culture
with mast cells did not affect the rate of proliferation or survival of ASM cells.
Conclusion Our ﬁndings do not support a role for increased airway smooth proliferation and
survival as the major mechanism driving ASM hyperplasia in asthma.
Keywords airway smooth muscle, apoptosis, asthma, mast cells, necrosis, proliferation,
survival
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Introduction
Asthma is a chronic inﬂammatory lung disease that leads
to signiﬁcant morbidity and mortality and its prevalence
is increasing [1]. Asthma is characterized by the presence
of variable airﬂow obstruction, airway inﬂammation, air-
way hyperresponsiveness (AHR) and airway remodelling
[2]. Mast cell microlocalization within the airway smooth
muscle (ASM) bundle is a characteristic feature of asthma
and is related to the severity of AHR [3–7].
Thefeatures ofairwayremodellinginclude depositionof
collagen in the lamina reticularis beneath the epithelial
basement membrane, increased numbers of subepithelial
myoﬁbroblasts, and increased glandular and ASM mass
[7–9]. The increased ASM mass may be because of a
combination of both ASM hyperplasia [8] and hypertro-
phy, which has been shown to increase with disease
severity and is associated with ﬁxed airﬂow obstruction
[8–10]. The cause of ASM hyperplasia in asthma is un-
known, but may be a consequence of increased ASM
proliferation or survival either because of intrinsic ab-
normalities in the ASM or because of interactions with the
local inﬂammatory environment. Reports have described
increased proliferation in ex vivo asthmatic ASM cells [11],
which has been attributed to alteration in mitochondrial
biogenesis [12]. However, this observation has not been
replicated in airway-derived myoﬁbroblasts [13] and
many studies have been unsuccessful in demonstrating
increased ASM proliferation in vivo [9, 10, 13, 14]. Mast
cells localized within the ASM bundlehavethe potential to
secrete a plethora of pro-inﬂammatory mediators, cyto-
kines and proteases through their chronic activation by
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stimuli [15, 16]. Tryptase, an important mast cell-derived
protease, is a potent stimulus for both DNA synthesis and
cell proliferation in ASM cells [4], while other studies have
shown that chymase another mast cell protease can have a
profound effect on ASM cell functionand airway remodel-
ling [17]. However, whether whole mast cells modulate
ASM proliferation or survival is unclear.
We hypothesized that: (1) there are intrinsic differences
between ASM from asthmatics and non-asthmatics with
increased proliferation and survival in asthma and (2)
these differential responses are modulated by interactions
with mast cells. To test our hypothesis, we assessed
proliferation, apoptosis and necrosis of ASM cells from
subjects with and without asthma, both alone and in
co-culture with mast cells.
Methods
Subjects
Asthmatic subjects and non-asthmatic controls were re-
cruited from Leicester, UK. Subjects with asthma had a
consistent history and objective evidence of asthma,
as indicated by one or more of the following: (i) metha-
choline AHR [PC20 forced expiratory volume in 1s
(FEV1)o8mg/mL]; (ii) 415% improvement in FEV1
15min after administration of 200mg of inhaled salbuta-
mol or (iii) 420% of maximum within-day amplitude
from twice daily peak expiratory ﬂow measurements over
14 days. Severity of asthma was deﬁned by Global
initiatives for asthma (GINA) treatment steps I–V [18].
The study was approved by the Leicestershire Research
Ethics Committees and all patients gave their written
informed consent.
Airway smooth muscle isolation and culture
Pure ASM bundles in bronchial biopsies were obtained
from ﬁbreoptic bronchoscopy (n=12, 11 subjects with
asthma, one non-asthmatic subject) and additional air-
ways isolated from lung resection (n=11). Subjects under-
going lung resection with moderate–severe airﬂow
obstruction were excluded. Only one of the 12 non-
asthmatic subjects had lung function impairment (FEV1%
predicted o80%) and airﬂow obstruction (FEV1/
FVCo70%). Clinical characteristics were as shown in
Table 1. Primary ASM were cultured in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) supplemented with 10%
fetal calf serum (FCS), 4mML -glutamine, 100U/mL
penicillin, 100mg/mL streptomycin and 0.25mg/mL
amphotericin (Invitrogen, Paisley, Scotland, UK). ASM
characteristics were determined by immunofluorescence,
flow cytometry and light microscopy with a-smooth
muscle actin–FITC direct conjugate and myosin indirectly
conjugated with FITC (Sigma, Poole, UK). ASM purity was
94(1.5)% and cells were used between passage 2 and 5.
Mast cells
Human lung mast cells (HLMC) (n=17) were obtained
from lung resection surgery by positive immunomagnetic
selection and cultured as described previously [19]. Final
mast cell purity was 499% and viability was 498%. The
human mast cell line (HMC-1) was a generous gift from
Dr. J. Butterﬁeld (Mayo Clinic, Rochester, MN, USA) and
was maintained in Iscove’s modiﬁed DMEM.
Non-asthmatic and asthmatic ASM cell assessment
Cell counts. ASM cells were seeded at a density of
5 10




(Sigma), and then exposed to 10% FCS over 10 days before
harvesting with trypsin and counting using trypan blue.
Carboxyﬂuorescein succinimidyl ester quantiﬁcation.
ASM cell proliferation was also assessed using the CFSE
Proliferation Kit (Invitrogen). ASM cells were seeded into
60mm tissue culture dishes and serum deprived for 24h
as per cell counts above. Cells were then labelled with 2.5
mM carboxyfluorescein succinimidyl ester (CFSE) for
15min in phosphate-buffered saline (PBS), before incuba-
tion in 10% FCS media for a further 30min to allow
cleavage of the acetate groups to yield highly fluores-
centCFSE. They were then incubated in 10% FCS at 371C
over 10 days. CFSE fluorescence was analysed using
single colour flow cytometry (BD FACSCanto; BD Phar-
mingen, Oxford, UK).
Thymidine assay. ASM cells were seeded in quadruplicate
in 96-well ﬂat-bottomed plates at a density of 1 10
3
cells/well in 10% FCS media over 48h. ASM cells were
Table 1. Clinical characteristics of airway smooth muscle donors
Asthma
GINA I=3; II=2; IV=4; V=2 Controls
Number 11 12
Gender, M/F 6/5 6/6
Age (years) 47 (3) 65 (4)
FEV1 (L) 2.5 (0.2) 2.1 (0.2)
FEV1% predicted 82 (6) 90 (5)
FEV1/FVC (%) 72 (2) 77 (2)
Inhaled corticosteroids (n)8 1
Long acting beta-agonist (n)6 0
Oral corticosteroids (n)2 0
Mean (SEM).
GINA, Global initiatives for asthma; FEV1, forced expiratory volume in
1s; FVC, forced vital capacity.
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pulsed with 1mCi
3H-thymidine (Amersham Pharmacia
Biotech Ltd., Buckinghamshire, UK) in 10% FCS media for
24h. Cells were washed with PBS and then precipitated
with TCA for 1h on ice and ﬁxed with ethanol overnight.
Cells were then lysed with 200mL SDS and added to 10mL
of scintillant. The solution was mixed and counts per
minute(CPM)wereassessedontheTRI-CARB
s scintillation
analyser (model 1500, Packard, Pangbourne, Berks, UK).
Cell metabolic activity assay. ASM cells were seeded in
triplicate in 96-well ﬂat bottomed plates at 1 10
3
cells/well in 10% FCS media over 48h at 371C and then
serum deprived for 24h. The CellTiter 96 Aqueous one
solution with the tetrazolium compound MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H tetrazolium] solution (Promega,
Southampton, UK) was then added to each well and
incubated at 371C for 3.5h. MTS is chemically reduced
by the cells to formazan, the absorbance of which at
490nm gives a measure of the dehydrogenase enzyme
activity found in metabolically active cells.
ASM/mast cell co-culture
As above ASM cells were seeded at a density of
5 10
4cells then serum deprived for 24h. ITS media was
then removed and replaced with either fresh ITS or 10%
FCS media   HMC-1 cells, goat polyclonal anti-human
IgE (1/500) (Sigma), HLMC alone or HLMC that had been
sensitized with 2.4mg/mL human myeloma IgE (Calbio-
chem-Novabiochem, Nottingham, UK) and then activated
with goat polyclonal anti-human IgE (1/500) in co-
culture. The ASM cells alone and with mast cells were
cultured over 10 days without refeeding. The mast cells
were added at a 1:4 (mast cell:ASM) ratio to reﬂect our
in vivo observations. After 10 days, the supernatant was
collected and the cell pellet was lysed in sterile de-ionized
water. ASM cell monoculture control cell counts were
established in parallel with mast cell co-cultures using the
Kimura staining, which readily differentiates red meta-
chromatic mast cells from unlabelled ASM cells.
Quantiﬁcation of histamine release by mast cells. Hista-
mine release by mast cells in co-culture was measured by
sensitive radioenzymatic assay based on the conversion of
histaminetomethylhistamineinthepresenceoftheenzyme
histamine-N-methyltransferase as described previously
[17]. Control HLMC were sensitized with IgE (2.4mg/mL) for
1h, washed and then activated with 1/500 anti-IgE for 1h.
Quantiﬁcation of ASM death by ﬂow cytometry. ASM
cultured alone was harvested using Accutase and the
percentage of apoptotic or necrotic cells was assessed by
suspending the ASM cells in 1  Annexin binding buffer
containing FITC-conjugated Annexin V [(1mL/200mL)
binding buffer] propidium iodide (PI) (0.5mg/mL; BD
Pharmingen), before analysis on the BD FACSCanto ﬂow
cytometer. Three colour ﬂow cytometry was conducted
with ASM co-cultured with HMC-1 or HLMC. The co-
cultured cells were stained with mAb antibody against
CD117 (clone:YB5.B8) (BD Pharmingen) and followed by
allphophycocyanincon (APC) secondary antibody to iden-
tify the HLMC. This allowed HLMC to be gated out of the
ASM cell analysis and then stained as above with Annexin
and PI. Appropriate isotype controls were used.
Morphological detection of ASM apoptosis. Nuclear mor-
phology of ASM was assessed by 40,6-diamidino-2-phe-
nylindole (DAPI) staining. For these experiments, ASM
were seeded at a density of 3 10
3cells/well into eight-
well chamber slides and incubated at 371C for 48h. The
media was then replaced with ITS media and incubated at
371C over 3 days. After 3 days of ASM cell serum
deprivation, ITS media was removed and replaced with
fresh ITS media HMC-1 cells or HLMC at 1:4 ratio. The
ASM cells were co-cultured with the mast cells over 10
days. ASM cells co-cultured with HLMC were stained with
directlyconjugatedmAbagainstRPE-CD117andindirectly
labelled with secondary NorthenLights RPE secondary
antibody (R&D Systems, Abingdon, UK). The cells were
then counterstained with DAPI and mounted with photo
bleach retardant mounting medium. CD117 was used to
identify the HLMC in the presence of ASM cells. ASM cells
cultured alone were stained with DAPI alone and mounted.
For each ASM mono- or co-culture, six random high-
powered ﬁelds (hpf) were examined for morphologic
features of apoptosis such as nuclear condensation and
fragmentation.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
4 (GraphPad, San Diego, CA, USA). Data are presented as
mean SEM and log normally distributed data was pre-
sented as geometric mean log SEM or  95% conﬁdence
interval. Comparisons across groups were performed by
ANOVA and Tukey’s post hoc test, and between groups by
paired and unpaired t-tests as appropriate. Differences
were considered significant when Po0.05.
Results
Non-asthmatic and asthmatic ASM cell proliferation and
metabolic activity
After 3, 7 and 10 days in culture, there was a signiﬁcant
difference in ASM cell number compared with baseline
counts (day 0) in both non-asthmatic [day 10 mean fold
difference (95% CI); 4 (2.43–6.52); P=0.0005; n=7] and
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CI); 5.86 (3.16–10.84); P=0.0004; n=7; Fig. 1a]. How-
ever, there was no signiﬁcant difference in the rate of
ASM proliferation between non-asthmatic and asthmatic
ASM cells (Fig. 1a). There was no relationship between
ASM proliferation and asthma severity (data not shown).
Example ﬂow cytometry histograms of CFSE staining of
asthmatic and non-asthmatic cells exposed to 10% FCS
are shown (Figs 1b and c). The geometric mean ﬂuores-
cence intensity (GMFI) markedly decreased from baseline
(day 0) after 3, 7 and 10 days conﬁrming that the ASM
cells were actively proliferating. However, we did not
observe differences between asthmatic (n=4) and non-
asthmatic ASM cells (n=4; Figs 1b–d). Similarly we were
unable to detect a difference in the tritiated thymidine
incorporation over 24h between ASM from asthmatics
(n=4) and controls [n=4; mean difference (95% CI); 78
( 147 to 303) cpm; P=0.43).
The absorbance by formazan seen at 490nm in the MTS
assay was increased in ASM cells (n=8) in media supple-
mented with 10% FCS compared with ASM cells in serum-
free media over 24h (data not shown). However, there was
no difference between non-asthmatic (n=4) and asth-
matic (n=4) ASM cells over 24h [OD mean difference
(95% CI);  0.03 ( 0.49–0.44)%; P=0.9] and 72h [OD
mean difference (95% CI); 0.14 ( 0.21–0.48)%; P=0.37].
Non-asthmatic and asthmatic ASM cell proliferation in
co-culture
ASM cells proliferated in the presence of 10% FCS, but not
ITS (Figs 2a–c). HMC-1 cells did not affect the ASM cell
Fig. 1. (a) Number of non-asthmatic (black line, n=7) and asthmatic (dashed line, n=7) airway smooth muscle (ASM) cells in response to exposure to
10% fetal calf serum (FCS) media over 10 days (data presented as mean fold change compared with control   SEM). Flow cytometric histogram
illustrating carboxyﬂuorescein succinimidyl ester (CFSE) ﬂuorescence in (b) non-asthmatic and (c) asthmatic ASM cells in response to exposure to 10%
FCS media over 7 days. (d) Non-asthmatic (n=4) and asthmatic (n=4) ASM cell proliferation was observed over 10 days. Data are presented as
geometric mean logSEM. Comparisons were made to CFSE staining at day 0 for non-asthmatic or asthmatic ASM cells. Po0.05, Po0.01,
Po0.001 for time-points compared with baseline and the P-values for comparisons between asthma and controls are as shown.
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days(Fig.2a).Therewerenodifferences betweenasthmatic
or non-asthmatic cells (data not shown). Similarly, co-
culture of HLMC with ASM in 10% FCS (n=3) or ITS media
(n=3) did not affect the cell number over 10 days (Fig. 2b).
Co-culture of ASM with IgE/anti-IgE activated HLMC
did not affect ASM proliferation over 10 days in the
presence of ITS media or media supplemented with 10%
FCS (n=4; Fig. 2c).
Histamine release in HLMC and ASM co-culture
HLMC alone (n=4) released signiﬁcantly more histamine
with IgE/anti-IgE activation at day 0 (918 101
ng/10
6cells) when compared with un-activated HLMC
(495 85ng/10
6cells; P=0.001). In co-culture, histamine
was readily measured at all time-points and increased
over time with concentrations at day 7 (P=0.03) and
10 (P=0.02) signiﬁcantly higher than day 1 (Fig. 3).
Histamine release by HLMC co-cultured with ASM cells
and IgE/anti-IgE activated was increased compared with
unstimulated co-cultured HLMC after 1 and 3 days
(Fig. 3).
ASM apoptosis and necrosis in co-culture
A combination of Annexin V staining and PI staining was
used to identify ASM cell apoptosis and necrosis in the
Fig. 2. (a) Number of airway smooth muscle (ASM) cells in response to exposure to 10% fetal calf serum (FCS) media   human mast cell line (HMC-1)
cells (n=6) or ITS media   HMC-1 cells over 10 days (n=7). (b) ASM cell counts in response to exposure of 10% FCS media   HLMC (n=3) or ITS media
  HLMC (n=7) over 10 days. (c) Number of ASM cells in response to either 10% FCS or ITS media alone  1:500 anti-IgE or co-cultured with activated
HLMC (IgE/anti-IgEactivation, n=4 ASM donors and four HLMC donors). Comparisons were made to control (day 0) within ASM status group using the
one sample t-test. Data presented as fold change geometric mean logSEM. (), ASM alone with 10% FCS; (
#), ASM   HMC-1 cells or HLMC in 10% FCS;
( ), ASM   HLMC (IgE-Anti-IgE 1/500 activated). Po0.05, Po0.01,
##Po0.01, Po0.001,  Po0.05 for time-points compared with baseline.
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1/PI
  cells were
classed as early apoptotic and Annexin V
1/PI
1 cells as
late apoptotic/necrotic [20]. There was no difference in
ASM cell percentage apoptosis and necrosis between ASM
derived from subjects with (n=4) or without asthma
(n=6; Fig. 4a). In co-culture CD117-APC labelled mast
cells were distinguished from ASM by ﬂow cytometry as
shown (Fig. 4b). The proportion of apoptotic and necrotic
cells was not signiﬁcantly affected by the presence of
HMC-1 cells over 3 days (n=7) or by HLMC over 10 days
(n=3; Figs 4c–f).
Example immunoﬂuorescent photomicrographs of
mast cells in co-culture with ASM are as shown (Figs
5a–e). Mast cells were identiﬁed as CD1171 and excluded
from examination of nuclear morphology. ASM nuclear
DAPI staining supported the Annexin V data as there was
no difference between the percentage apoptotic cells from
subjects with (n=7) and without asthma (n=9; Fig. 5d).
ASM cells were unaffected by the presence of HMC-1 cells
over 3 days (n=7; Fig. 5e) and 10 days for the HLMC
(n=9; Fig. 5f).
Using both DAPI and Annexin V/PI staining, no differ-
ence in the effect of HMC-1 cells was observed between
cells derived from asthmatic subjects compared with non-
asthmatic controls (data not shown).
Discussion
We found no differences in proliferation or survival of
ASM from subjects with and without asthma. Co-culture
of ASM with unstimulated or stimulated mast cells did not
modulate ASM proliferation or survival. We therefore
reject our hypothesis that there are intrinsic differences
in proliferation and survival of asthmatic ASM augmen-
ted by the co-localization of mast cells. Our ﬁndings do
not support a role for increased ASM proliferation and
survival as the major mechanism driving ASM hyper-
plasia in asthma.
The view that there is increased proliferation of airway
mesenchymal cells in asthma is contentious. Some reports
supported this view [11, 12], but more recent work has
been unable to replicate these ﬁndings [13]. Here we did
not identify a difference in proliferation between cells
from subjects with and without asthma. The strength of
our assertion comes from the consistency in our ﬁndings
using several techniques and although our control sub-
jects were not all healthy controls, only one out of 12 had
spirometric evidence of chronic obstructive pulmonary
disease. An alternative explanation for the presence of
ASM hyperplasia in asthma is that there is differential
survival of ASM cells. We report for the ﬁrst time the
proportion of apoptotic or necrotic ASM cells from sub-
jects with and without asthma. No differences were
observed between disease and controls using complemen-
tary techniques of Annexin V/PI staining and nuclear
morphology. Therefore, in contrast to the consistent
observation of intrinsic differences between the synthetic
function of ASM from asthmatics compared with non-
asthmatics [5, 21–23], we were unable to demonstrate
differences in ASM in terms of proliferation or survival.
Importantly, in asthma mast cells are localized to the
ASM bundle, which is a consistent feature of this disease
[3–7]. Mast cell products such as b-tryptase [4, 24],
histamine [25] and LTD4 [26], have been implicated in
modulating ASM proliferation. We therefore predicted
that co-culture of mast cells and ASM would augment
proliferation and reduce apoptosis. However, we were
unable to demonstrate an effect on ASM proliferation or
survival by mast cells even after IgE/anti-IgE stimulation.
This illustrates how effects of individual mediators may
not reﬂect whole cell co-culture and underpins the im-
portance of co-culture studies. Interestingly, a recent
paper by Ceresa et al. [27] found that ASM proliferation
was decreased in 3-D collagen gel vs. 2-D culture. This
was associated with de-differentiation of the ASM cells.
Co-culture with HMC-1 cells promoted a more ASM
phenotype with increased a-smooth muscle actin expres-
sion and the re-establishment of the rate of proliferation.
This is in keeping with our work that demonstrated mast
cells drive ASM differentiation to a more contractile
phenotype via autocrine up-regulation of TGF-b1 [28].
Fig. 3. Airway smooth muscle (ASM) cells (n=4) were co-cultured with
un-activated human lung mast cells (HLMC, n=4) alone and activated
HLMC (n=4, IgE/Anti-IgE) over 10 days in ITS media. Histamine
concentrations were measured in culture supernatants and corrected for
mast cell number. Constitutive histamine release was demonstrated with
un-activated HLMC co-culture, which was augmented in IgE/anti-IgE
activated HLMC over 1 and 3 days. Data presented as mean SEM;
P-values are as shown.
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cells affect ASM proliferation or survival it remains a
possibility that in vivo these interactions may have im-
portant functional effects which need to be further de-
ﬁned.
Our ﬁndings have implications for our understanding
of the cause of ASM hyperplasia in asthma. Current
dogma suggests that ASM hyperplasia is a consequence
of increased ASM proliferation [11]. Our ﬁndings do not
support a role for proliferation or survival, which suggests
that an alternative mechanism may be important in
driving ASM hyperplasia such as increased recruitment
of ASM or its progenitors [29, 30] to the ASM bundle. This
view ﬁnds support with increased ASM progenitors in the
peripheral blood, lamina propria and most importantly
within the ASM bundle of asthmatics [30–32]. We have
proposed that the CCL19/CCR7 axis and platelet-derived
growth factor may be important in the recruitment of
myoﬁbroblasts and ﬁbrocytes, respectively, towards the
ASM bundle [29, 30].
One potential criticism of our ﬁndings is that we have
restricted our study to ex vivo primary cultures and have
Fig. 4. Apoptosis and necrosis was assessed by ﬂow cytometry with FITC-Annexin V/PI binding in airway smooth muscle (ASM) cells alone or co-
cultured with human mast cell line (HMC-1) or human lung mast cells (HLMC) labelled with CD117-APC. (a) Percentage apoptotic ASM cells revealed by
Annexin V
1/PI
  and necrotic cells revealed by Annexin V
1/PI
1 cells of non-asthmatic (n=6) and asthmatic (n=4) ASM cells. (b) Representative ﬂow
cytometry dot plots illustrating day 7 co-culture of ASM cells and HLMC labelled with CD117-APC. (c) Percentage of apoptotic ASM cells   HMC-1 cells
and (d) percentage of necrotic ASM cells   HMC-1 cells (n=7 paired t-test), (e) Percentage of apoptotic ASM cells   HLMC cells and (f) percentage of
necrotic ASM cells (n=3). Data presented as mean SEM; P-values are as shown.
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may have not reﬂected the complex interactions with the
microenvironment in tissue. However, our conﬁdence in
our data is supported by the consistent lack of evidence in
favour of increased ASM proliferation in vivo [9, 10, 13,
14]. Our view is also strengthened by the lack of an effect
on ASM proliferation or survival even following mast cell
activation. Interestingly, in co-culture with ASM, mast
cells are in an ‘activated state’ evidenced by increased
degranulation and constitutive release of histamine [33].
This effect is IgE-independent and suggests that in asth-
ma, ASM will be exposed to high local concentrations of
mast cell mediators. Importantly, we have observed other
profound effects in whole co-culture without mast cell
stimulation [28] and therefore feel conﬁdent that we have
not overlooked important mast cell mediated effects on
ASM survival or proliferation. An alternative explanation
for our lack of difference in ASM proliferation between
asthma vs. non-asthma maybe related to seeding density.
However, ASM and myoﬁbroblast proliferation has pre-
viously been reported to be increased in models using
both higher [34] and lower seeding densities [35], but also
to be unaffected in a study using higher density [36].
Taken together these data suggest that differences in
seeding density are unlikely to provide an explanation
for the inconsistency between reports. In spite of our
inability to identify changes in proliferation and survival
of ASM asthmatic, it is important to note that asthma is a
heterogeneous condition [37] and therefore, we are unable
to exclude the possibility that increased proliferation and
survival of ASM may be a feature of some asthmatics.
In conclusion, proliferation and survival of ASM from
asthmatics and non-asthmatics is similar. Although mast
cell–ASM interactions may play a key role in some
important aspects of asthma, mast cell–ASM co-culture
does not affect ASM proliferation or survival. ASM
Fig. 5. (a) Representative micrographs at day 3 showing 40,6-diamidino-2-phenylindole (DAPI) staining of airway smooth muscle (ASM) cells in the
presenceof ITSmedia alone, (b) in co-culture withhumanmast cellline(HMC-1) cells [stainedwithDAPI (blue)and overlaidwithanti-CD117 (red)]. (c)ASM
cells in co-culture with human lung mast cells (HLMC) cells (stained with DAPI and overlaid with anti-CD117). (d) Percentage of apoptotic nuclei of non-
asthmatic (n=9) and asthmatic ASM cells (n=7) identiﬁed by nuclear morphology over 10 days. (e) Percentage of apoptotic nuclei for ASM cells in ITS
media  HMC-1 cells over 3 days (n=7 )a n d( f )A S Mc e l l si nI T Sm e d i a  HLMC over 10 days (n=9). Data presented asmean SEM; P-values are as shown.
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286 D. Kaur et alproliferation and survival is therefore unlikely to be a key
determinant in the development of ASM hyperplasia in
asthma.
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